Biopharmaceutical New Technologies (BioNTech), which developed an mRNA Covid-19 vaccine together with Pfizer, is establishing its Southeast Asia regional headquarters in Singapore, announced Lawrence Wong during his Budget speech today (February 18).
It plans to build a fully integrated mRNA manufacturing facility in Singapore, which will be operational as early as next year.
The new facility will boost BioNTech’s regional and global supply capacity for its growing pipeline of novel mRNA-based product candidates.
Together with other new investments and plans to build business and headquarter operations in Singapore, this will create more jobs for Singaporeans.
Moderna is doing the same too
Separately, biotechnology company Moderna has also announced plans to set up a new subsidiary in Singapore, along with three additional ones in Malaysia, Taiwan and Hong Kong.
The new subsidiaries will add to the Covid-19 vaccine manufacturer’s presence in the Asia-Pacific region. It currently has offices in Japan, South Korea, and Australia.
It did not mention when the Singapore subsidiary will be set up in its media statement, but said that Moderna will be recruiting a team in Singapore as the company’s mRNA therapeutics business grows.
The team will cover a range of functions in areas such as medical, regulatory, pricing, reimbursement, market access, government affairs, and commercial operations.
Featured Image Credit: Financial Times